loader from loading.io

Symptoms and Incidence of RCVS; Optimizing Stroke Prevention in Atrial Fibrillation

Neurology® Podcast

Release Date: 07/19/2021

Impact of Thymectomy on Myasthenia Gravis Remission show art Impact of Thymectomy on Myasthenia Gravis Remission

Neurology® Podcast

Dr. Stacey Clardy discusses the impact of surgical approaches to thymectomy upon remission rates in myasthenia gravis with Dr. Joseph Shrager.

info_outline
Symptoms and Incidence of RCVS; Optimizing Stroke Prevention in Atrial Fibrillation show art Symptoms and Incidence of RCVS; Optimizing Stroke Prevention in Atrial Fibrillation

Neurology® Podcast

In the first segment, Will Rondeau discusses the symptoms, incidence, and resource utilization of reversible cerebrovascular vasoconstriction syndrome with Dr. Jessica Magid-Bernstein. In the second part of the podcast, Dr. Andy Southerland discusses the optimization of atrial fibrillation treatment and stroke prevention with Dr. Seemant Chaturvedi.

info_outline
Illness in Overseas U.S. Embassies Employees; Afferent Baroreflex Failure show art Illness in Overseas U.S. Embassies Employees; Afferent Baroreflex Failure

Neurology® Podcast

In the first segment, Dr. Alex Menze talks with Dr. Clifford Saper about Havana Syndrome and recent attacks on American diplomats. In the second part of the podcast, Dr. Jeff Ratliff discusses the natural history of afferent baroreflex failure with Dr. Guillaume Lamotte.

info_outline
Evaluations in First Episode Psychosis; Dr. Daniel Gibbs on his Battle with Alzheimer's show art Evaluations in First Episode Psychosis; Dr. Daniel Gibbs on his Battle with Alzheimer's

Neurology® Podcast

In the first segment, Dr. Gregg Day speaks with Dr. Josep Dalmau about NMDAR antibodies in patients with first episode psychosis and the utility of criteria for autoimmune psychosis. In the second part of the podcast, Dr. Jeff Burns talks to neurologist Dr. Daniel Gibbs about his Alzheimer’s disease diagnosis and experience participating in a clinical trial for aducanumab.

info_outline
Management of Neurologic Conditions in Pregnancy (Neurology Recall July 2021) show art Management of Neurologic Conditions in Pregnancy (Neurology Recall July 2021)

Neurology® Podcast

This month's replay of past episodes showcases a selection of interviews on the impact of pregnancy on various neurologic disorders, featuring Drs. Page Pennell, Paula Emanuela Voinescu, Mary Angela O'Neal, Emma Ciafaloni, Raed Alroughani, Rae Bacharach, Annette Langer-Gould, Nicolas Collongues, and Petra Ijäs.

info_outline
SPECIAL REPORT: A Discussion with Mary Post (Part 2) show art SPECIAL REPORT: A Discussion with Mary Post (Part 2)

Neurology® Podcast

This second installment in our two-part series features Dr. Stacey Clardy in conversation with Mary Post, CEO of the American Academy of Neurology.

info_outline
SPECIAL REPORT on Aducanumab Approval: A Pulitzer Prize-winning Journalist's Perspective show art SPECIAL REPORT on Aducanumab Approval: A Pulitzer Prize-winning Journalist's Perspective

Neurology® Podcast

Dr. Gregg Day speaks with Pam Belluck, an award-winning journalist at the New York Times, about her coverage of the recent FDA approval of aducanumab for Alzheimer disease treatment.

info_outline
SPECIAL REPORT: A Discussion With Mary Post (Part 1)  show art SPECIAL REPORT: A Discussion With Mary Post (Part 1)

Neurology® Podcast

This first installment of a two-part series features Dr. Stacey Clardy in conversation with Mary Post, CEO of the American Academy of Neurology.

info_outline
SPECIAL REPORT on Aducanumab Approval: Discussion with Cognitive Behavioral Neurologists show art SPECIAL REPORT on Aducanumab Approval: Discussion with Cognitive Behavioral Neurologists

Neurology® Podcast

Dr. Jeff Burns, Director of the University of Kansas Alzheimer’s Disease Center, speaks with Dr. Ron Petersen, Director of the Mayo Clinic Alzheimer's Disease Center, about the recent FDA approval of aducanumab for the treatment of Alzheimer disease.

info_outline
SPECIAL REPORT on Aducanumab Approval: Steve Pearson of ICER Discusses the Economic and Clinical Impact show art SPECIAL REPORT on Aducanumab Approval: Steve Pearson of ICER Discusses the Economic and Clinical Impact

Neurology® Podcast

Dr. Jason Crowell speaks with Dr. Steve Pearson, President of the Institute for Clinical and Economic Review, about the clinical and economic impact of aducanumab, a drug recently approved by the FDA for the treatment of Alzheimer disease.

info_outline
 
More Episodes

In the first segment, Will Rondeau discusses the symptoms, incidence, and resource utilization of reversible cerebrovascular vasoconstriction syndrome with Dr. Jessica Magid-Bernstein. In the second part of the podcast, Dr. Andy Southerland discusses the optimization of atrial fibrillation treatment and stroke prevention with Dr. Seemant Chaturvedi.